Business Description
Centessa Pharmaceuticals PLC
ISIN : US1523091007
Share Class Description:
CNTA: ADRTotal Employee Number:
129Description
Centessa Pharmaceuticals PLC is a clinical-stage biotechnology company pioneering a new class of therapeutics in orexin-based neuroscience. The group is developing a franchise of small molecule orexin receptor 2 (OX2R) agonists designed to address neuroscience diseases underpinned by dysregulation of wakefulness, attention, cognition, mood, and other symptoms, each grounded in the shared biology of the orexin pathway. The company's programs and Pipeline are the Orexin Receptor 2 Agonist Program and LockBody Technology Platform.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.33 | |||||
Equity-to-Asset | 0.76 | |||||
Debt-to-Equity | 0.24 | |||||
Debt-to-EBITDA | -0.5 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 15.6 | |||||
3-Year EPS without NRI Growth Rate | 13.9 | |||||
3-Year FCF Growth Rate | 12.8 | |||||
3-Year Book Growth Rate | -0.1 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 92.55 | |||||
9-Day RSI | 84.24 | |||||
14-Day RSI | 78.18 | |||||
3-1 Month Momentum % | 38.54 | |||||
6-1 Month Momentum % | 60.39 | |||||
12-1 Month Momentum % | 202.82 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 9.53 | |||||
Quick Ratio | 9.53 | |||||
Cash Ratio | 7.56 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -16.3 | |||||
Shareholder Yield % | -0.27 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
FCF Margin % | -1391.97 | |||||
OCF Margin % | -1391.97 | |||||
ROE % | -61.22 | |||||
ROA % | -44.8 | |||||
ROIC % | -97.45 | |||||
3-Year ROIIC % | 0.54 | |||||
ROC (Joel Greenblatt) % | -2152.77 | |||||
ROCE % | -45.17 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 364.86 | |||||
PB Ratio | 12.86 | |||||
Price-to-Tangible-Book | 12.86 | |||||
EV-to-EBIT | -25.66 | |||||
EV-to-EBITDA | -25.76 | |||||
EV-to-Revenue | 407.24 | |||||
EV-to-FCF | -29.26 | |||||
| Price-to-Net-Current-Asset-Value | 32.14 | |||||
| Price-to-Net-Cash | 51.27 | |||||
Earnings Yield (Greenblatt) % | -3.9 | |||||
FCF Yield % | -3.33 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CNTA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Centessa Pharmaceuticals PLC Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 15 | ||
| EPS (TTM) ($) | -1.79 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | 1.29 | ||
| 3-Year Sortino Ratio | 3.71 | ||
| Volatility % | 68.9 | ||
| 14-Day RSI | 78.18 | ||
| 14-Day ATR ($) | 0.170216 | ||
| 20-Day SMA ($) | 39.9875 | ||
| 12-1 Month Momentum % | 202.82 | ||
| 52-Week Range ($) | 12.78 - 40.56 | ||
| Shares Outstanding (Mil) | 154.73 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Centessa Pharmaceuticals PLC Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Centessa Pharmaceuticals PLC Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-05 | In 110 days | ||
| Second quarter earnings results for 2026 | 2026-08-12 | In 25 days | ||
| General meeting for 2026 | 2026-06-12 09:30 | 39.77 (-0.03%) | ||
| First quarter earnings results for 2026 | 2026-05-05 | 39.70 (+0.48%) | ||
| Annual report for 2025 | 2026-03-31 | 27.58 (-3.67%) | ||
| Jefferies Biotech on the Beach Summit | 2026-03-11 | 27.59 (+5.47%) | ||
| Leerink Partners Global Healthcare Conference | 2026-03-10 08:00 | 26.09 (+1.05%) | ||
| TD Cowen 46th Annual Health Care Conference | 2026-03-03 15:10 | 26.51 (-0.38%) | ||
| Guggenheim Emerging Outlook: Biotech Summit | 2026-02-12 13:00 | 23.56 (+0.64%) | ||
| Oppenheimer Movers in Rare Disease Summit | 2025-12-11 | 29.57 (+1.58%) |
Show
Entries
Centessa Pharmaceuticals PLC Frequently Asked Questions
What is Centessa Pharmaceuticals PLC(CNTA)'s stock price today?
The current price of CNTA is $40.50. The 52 week high of CNTA is $40.56 and 52 week low is $12.78.
When is next earnings date of Centessa Pharmaceuticals PLC(CNTA)?
The next earnings date of Centessa Pharmaceuticals PLC(CNTA) is 2026-08-12 Est..
Does Centessa Pharmaceuticals PLC(CNTA) pay dividends? If so, how much?
Centessa Pharmaceuticals PLC(CNTA) does not pay dividend.
Guru Commentaries on NAS:CNTA
No articles.
Press Release
Articles on Centessa Pharmaceuticals PLC
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers